Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-07-01

Reporting Person: BRADSHER NEAL C (Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	OPTION TO PURCHASE COMMON SHARES	$2.86	A	50000	Acquired	2031-07-01	COMMON SHARES (50000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTION TO PURCHASE COMMON SHARES	$0.8263	2030-07-01	COMMON SHARES (40000)	40000	Direct
OPTION TO PURCHASE COMMON SHARES	$1.03	2029-06-30	COMMON SHARES (40000)	40000	Direct
OPTION TO PURCHASE COMMON SHARES	$1.67	2023-06-30	COMMON SHARES (49440)	49440	Direct
OPTION TO PURCHASE COMMON SHARES	$2.55	2022-06-30	COMMON SHARES (24720)	24720	Direct

Footnotes

F1: These options will vest and become exercisable on July 1, 2022, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.

F2: These options were granted to the Reporting Person by the Issuer on July 1, 2021 as director compensation pursuant to the Issuer's 2012 Equity Incentive Plan, as amended.

F3: These options are currently exercisable.